Lundbeck has expanded its pharma alliance with Otsuka Pharmaceutical Co to include development and commercialisation of the alcohol dependence drug Selincro in Japan.
Selincro (nalmefene) was approved by the European Medicines Agency earlier this year.
The two partners say the first Phase III study for Japan will be initiated during 2014.
Lundbeck will pocket a 50 million euro fee, finance the development costs and have an option to co-promote in Japan for this pharma alliance.
If all milestones are achieved, the total value of the agreement to the Danish drugmaker would be 100 million euros, plus royalties.
For further deal information visit Current Agreements (subscription required)
Read: more on Lundbeck company profile, recent partnering, M&A and financing news and articles
Read: more on Otsuka company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Lundbeck
Report: Partnering Deals and Alliances with Otsuka
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity